VIDEO: Optogenetic therapy trial in retinitis pigmentosa meets safety, efficacy endpoints
Click Here to Manage Email Alerts
CHICAGO — In this Healio Video Perspective from the AAO meeting, Allen C. Ho, MD, of Wills Eye Hospital shares promising results of a phase 2b/3 trial investigating MCO-010 optogenetic therapy for the treatment of retinitis pigmentosa.
The trial, which included 27 participants, met its safety and efficacy endpoints at 52 weeks and 76 weeks. The data support Nanoscope Therapeutics’ plan to submit a biologics license application for the mutation-agnostic gene therapy in 2025, according to Ho.
“I think the RESTORE trial represents some real hope for patients with advanced retinal degenerations,” he said. “At some point in the not too distant future, we may have hope in making the truly blind see again.”
Collapse
Ho AC, et al. Efficacy and safety of MCO-010 optogenetic therapy for vision restoration in patients with severe vision loss due to RP: Two-year topline results from a phase 2b/3 randomized, sham-controlled clinical trial (RESTORE). Presented at: American Academy of Ophthalmology meeting; Oct. 18-21, 2024; Chicago.
Read more about
Click Here to Manage Email Alerts